Clinicopathologic and Histochemical Study of Ovarian Clear Cell Carcinoma

Nordback, Isto; Lauslahti, K

doi:10.1002/j.1879-3479.1980.tb00251.x

Cited by 1 publication

(1 citation statement)

References 14 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histologically, CCOC cells are “clear” due to the high cytoplasmic glycogen content that is an artifact of H & E staining [11], [12]. CCOC has been found to have ultrastructural similarity to clear cell carcinoma of the vagina and endometrium.…”

Section: Introductionmentioning

confidence: 99%

Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers

et al. 2011

View full text Add to dashboard Cite

Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer prognosis than serous and endometrioid histotypes. Despite this, patients with these tumors are treated in a similar fashion as all other ovarian cancers. Previous genomic analysis has suggested that clear cell cancers represent a unique tumor subtype. Here we generated the first whole genomic expression profiling using epithelial component of clear cell ovarian cancers and normal ovarian surface specimens isolated by laser capture microdissection. All the arrays were analyzed using BRB ArrayTools and PathwayStudio software to identify the signaling pathways. Identified pathways validated using serous, clear cell cancer cell lines and RNAi technology. In vivo validations carried out using an orthotopic mouse model and liposomal encapsulated siRNA. Patient-derived clear cell and serous ovarian tumors were grafted under the renal capsule of NOD-SCID mice to evaluate the therapeutic potential of the identified pathway. We identified major activated pathways in clear cells involving in hypoxic cell growth, angiogenesis, and glucose metabolism not seen in other histotypes. Knockdown of key genes in these pathways sensitized clear cell ovarian cancer cell lines to hypoxia/glucose deprivation. In vivo experiments using patient derived tumors demonstrate that clear cell tumors are exquisitely sensitive to antiangiogenesis therapy (i.e. sunitinib) compared with serous tumors. We generated a histotype specific, gene signature associated with clear cell ovarian cancer which identifies important activated pathways critical for their clinicopathologic characteristics. These results provide a rational basis for a radically different treatment for ovarian clear cell patients.

show abstract

Section: Introductionmentioning

confidence: 99%